Intervention Review

You have free access to this content

Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus

  1. Virginia Fernandes Moça Trevisani1,*,
  2. Aldemar A Castro2,
  3. João Ferreira Neves Neto3,
  4. Álvaro N Atallah4

Editorial Group: Cochrane Musculoskeletal Group

Published Online: 28 FEB 2013

Assessed as up-to-date: 16 NOV 2012

DOI: 10.1002/14651858.CD002265.pub3


How to Cite

Fernandes Moça Trevisani V, Castro AA, Ferreira Neves Neto J, Atallah ÁN. Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus. Cochrane Database of Systematic Reviews 2013, Issue 2. Art. No.: CD002265. DOI: 10.1002/14651858.CD002265.pub3.

Author Information

  1. 1

    Universidade Federal de São Paulo, Rheumatology/Internal Medicine and Therapeutics, São Paulo, São Paulo, Brazil

  2. 2

    State University of Heath Science, Department of Public Health, Maceió, Alagoas, Brazil

  3. 3

    Universidade Federal de São Paulo, Surgery, São Paulo, São Paulo, Brazil

  4. 4

    Escola Paulista de Medicina, Universidade Federal de São Paulo, Brazilian Cochrane Centre, São Paulo, São Paulo, Brazil

*Virginia Fernandes Moça Trevisani, Rheumatology/Internal Medicine and Therapeutics, Universidade Federal de São Paulo, Rua Marie Satzke 119, São Paulo, São Paulo, 04664-150, Brazil. vmoca@uol.com.br. cochrane.dmed@epm.br.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 28 FEB 2013

SEARCH

[Figure 1]
Figure 1. Study flow diagram.
[Figure 2]
Figure 2. 'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
[Figure 3]
Figure 3. 'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Cyclophosphamide versus methylprednisolone, Outcome 1 Response to treatment.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Cyclophosphamide versus methylprednisolone, Outcome 2 SLICC.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Cyclophosphamide versus methylprednisolone, Outcome 3 SLEDAI.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Cyclophosphamide versus methylprednisolone, Outcome 4 Prednisone sparing.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Cyclophosphamide versus methylprednisolone, Outcome 5 Seizures.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Cyclophosphamide versus methylprednisolone, Outcome 6 Adverse events.
[Analysis 1.7]
Analysis 1.7. Comparison 1 Cyclophosphamide versus methylprednisolone, Outcome 7 Completion of the protocol after 2 years.